This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brizel, D. M. Articles by Esclamado, R. Search for Related Content PubMed PubMed Citation Articles by Brizel, D. M. Articles by Esclamado, R.

Concurrent Chemoradiotherapy for Locally Advanced, Nonmetastatic, Squamous Carcinoma of the Head and Neck: Consensus, Controversy, and Conundrum

David M. Brizel, Ramon Esclamado

From the Department of Radiation Oncology and the Division of Otolaryngology, Department of Surgery, Duke University Medical Center, Durham, NC

Address reprint requests to David M. Brizel, MD, Department of Radiation Oncology, Box 3085, Duke University Medical Center, Durham, NC 27710, e-mail: david.brizel{at}duke.edu

Radiotherapy and concurrent chemotherapy (CRT) is superior to radiotherapy alone for the treatment of locally advanced, nonmetastatic squamous carcinoma of the head and neck (HNC). Three issues affect the use of CRT as primary treatment for advanced HNC. The first issue is the definition of advanced stage and the initial therapeutic choice of surgery or CRT and the role of post-CRT neck dissection. Function preservation considerations should guide the choice between surgery and CRT for patients with resectable disease. Fluorodeoxyglucose–positron emission tomography scanning may identify patients who require adjuvant neck dissection. The second issue is optimization of radiotherapy and chemotherapy schedules. Ideally, concurrent chemotherapy should be incorporated into radiotherapy (RT) regimens that would constitute optimal therapy were RT to be administered as single-modality treatment. Modified fractionation schemes constitute optimal single-modality RT. Platinum schedules other than bolus dosing every 3 to 4 weeks are effective and may be less toxic. The third issue is integration of biologically targeted therapy into CRT treatment programs. Epidermal growth factor receptor blockade enhances the effectiveness of RT alone. Its role and that of angiogenic blockade in CRT are under investigation.

Authors' disclosures of potential con- flicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				E. Bolke, M. Peiper, S. Gripp, and J. B. Vermorken Chemotherapy in Unresectable Head and Neck Cancer N. Engl. J. Med., March 6, 2008; 358(10): 1075 - 1075. [Full Text] [PDF]

				A. Raykher, L. Russo, M. Schattner, L. Schwartz, B. Scott, and M. Shike Enteral Nutrition Support of Head and Neck Cancer Patients Nutr Clin Pract, February 1, 2007; 22(1): 68 - 73. [Abstract] [Full Text] [PDF]

				A. A. Forastiere, A. Trotti, D. G. Pfister, and J. R. Grandis Head and Neck Cancer: Recent Advances and New Standards of Care J. Clin. Oncol., June 10, 2006; 24(17): 2603 - 2605. [Full Text] [PDF]